Human BACE-1 in complex with 3-(ethylamino)-N-((1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-5-(2-oxo-1-pyrrolidinyl)benzamide

B. Clarke, G. Wayne, Rosalie Matico(GlaxoSmithKline (United States)), Julie A. Hawkins(Charles River Laboratories (United Kingdom)), J. Mosley(GlaxoSmithKline (United Kingdom)), Sharon Sweitzer(GlaxoSmithKline (United States)), David Riddell(Eli Lilly (United States)), Alexander G. O’Brien(Scripps Research Institute), Sally Redshaw(GlaxoSmithKline (United Kingdom)), Steven J. Stanway(GlaxoSmithKline (United Kingdom)), V. Soleil(GlaxoSmithKline (United Kingdom)), David T. MacPherson(GlaxoSmithKline (United Kingdom)), A. Naylor, G. Maile(GlaxoSmithKline (United Kingdom)), Kevin M. Smith(Louisiana State University), P. Theobald, D. Vesey(GlaxoSmithKline (United Kingdom)), J. Ward, R. Dunsdon(GlaxoSmithKline (United Kingdom)), Paul Rowland(GlaxoSmithKline (United Kingdom)), Izhar Hussain, Geoffrey Stemp(GlaxoSmithKline (United Kingdom)), C. Dingwall, D.S. Walter, Phillip J. Milner(Cornell University), Andrew Faller(GlaxoSmithKline (United Kingdom)), Emmanuel H. Demont(Age UK)
Unknown
December 6, 2007
Cited by 0


Related Papers